• Vaccine Name: rBPIV3-RSV-G
• Target Pathogen: Human Respiratory Syncytial Virus
• Target Disease: Respiratory tract disease
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: G and F protein (Falsey et al., 2022)
• G gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Preparation: bPIV3 as a virus vaccine vector with the introduction of the RSV attachment (G) and fusion (F) genes into the bPIV3 RNA genome(Haller et al., 2003)
• Immunization Route: Intramuscular injection (i.m.)

Hamster Response

• Vaccination Protocol: Hamsters were infected intranasally with 1×106  p.f.u. r-bPIV3, bPIV3/RSV(I), RSV or placebo (Opti-MEM) in a 0·1 ml volume(Haller et al., 2003)
• Challenge Protocol: Animals were inoculated on day 21 intranasally with 1×106 p.f.u. of hPIV3 or RSV. (Haller et al., 2003)
• Efficacy: The recombinant virus expressed the RSV G and F proteins sufficiently to evoke a protective immune response in hamsters upon challenge with RSV or human PIV3 and to elicit RSV neutralizing and PIV3 haemagglutinin inhibition serum antibodies. In effect, a bivalent vaccine was produced that could protect vaccinees from RSV as well as PIV3(Haller et al., 2003)